|Bid||133.86 x 900|
|Ask||142.70 x 1200|
|Day's Range||134.58 - 135.30|
|52 Week Range||107.77 - 136.70|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.15%|
Wall Street has been on a roller-coaster ride this year. Yet, the small-cap segment of the broader market has been outperforming, defying extremely volatility. This is especially true as the Russell 2000 is nearing its record levels with just less than 1% away from its peak.Source: ShutterstockWhy Small Caps?
Of the six analysts covering Atara Biotherapeutics in January 2018, four analysts have given the stock a “buy” or a higher rating, while two analysts have given it a “hold” rating. By comparison, of the 26 analysts covering Amgen (AMGN) in January 2018, 12 analysts have given the company a “buy” or a higher rating, while 14 analysts have given it a “hold” rating. Of the 31 analysts covering Celgene (CELG) in January 2018, 17 analysts have given the stock a “buy” or a higher rating, while 13 analysts have given the stock a “hold” rating, and only one analyst has given it a “sell” rating.
How Is Accelerate Diagnostics Positioned at the Start of 2018? The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17. For fiscal 2017, Accelerate Diagnostics is expected to report revenues of $5 million, while peers Becton Dickinson (BDX), Bruker (BRKR), and Thermo Fisher Scientific (TMO) are expected to report revenues of $12 billion, $1.7 billion, and $20.5 billion, respectively.